A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
- 13 Mar 2018 Planned End Date changed from 2 May 2019 to 17 Dec 2018.
- 13 Mar 2018 Planned primary completion date changed from 4 Sep 2018 to 13 Jul 2018.
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.